Background: Despite its approval in 1953, hydralazine hydrochloride continues to be used in the management of resistant hypertension, a condition frequently managed by nephrologists and other clinicians. Hydralazine hydrochloride undergoes metabolism by the N-acetyltransferase 2 (NAT2) enzyme. NAT2 is highly polymorphic as approximately 50% of the general population are slow acetylators. In this review, we first evaluate the link between NAT2 genotype and phenotype. We then assess the evidence available for genotype-guided therapy of hydralazine, specifically addressing associations of NAT2 acetylator status with hydralazine pharmacokinetics, antihypertensive efficacy, and toxicity. Summary: There is a critical need to use hydralazine in some patients with resistant hypertension. Available evidence supports a significant link between genotype and NAT2 enzyme activity as 29 studies were identified with an overall concordance between genotype and phenotype of 92%. The literature also supports an association between acetylator status and hydralazine concentration, as fourteen of fifteen identified studies revealed significant relationships with a consistent direction of effect. Although fewer studies are available to directly link acetylator status with hydralazine antihypertensive efficacy, the evidence from this smaller set of studies is significant in 7 of 9 studies identified. Finally, 5 studies were identified which support the association of acetylator status with hydralazine-induced lupus. Clinicians should maintain vigilance when prescribing maximum doses of hydralazine. Key Messages: NAT2 slow acetylator status predicts increased hydralazine levels, which may lead to increased efficacy and adverse effects. Caution should be exercised in slow acetylators with total daily hydralazine doses of 200 mg or more. Fast acetylators are at risk for inefficacy at lower doses of hydralazine. With appropriate guidance on the usage of NAT2 genotype, clinicians can adopt a personalized approach to hydralazine dosing and prescription, enabling more efficient and safe treatment of resistant hypertension.

1.
Carey
RM
,
Calhoun
DA
,
Bakris
GL
,
Brook
RD
,
Daugherty
SL
,
Dennison-Himmelfarb
CR
, et al.
Resistant hypertension: detection, evaluation, and management: a scientific statement from the american heart association
.
Hypertension
.
2018
;
72
(
5
):
e53
90
.
2.
McDonagh
EM
,
Boukouvala
S
,
Aklillu
E
,
Hein
DW
,
Altman
RB
,
Klein
TE
.
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
.
Pharmacogenet Genomics
.
2014
;
24
(
8
):
409
25
.
3.
NCBI
.
Genetic Testing Registry. [cited 2020 June 8]. Available from:
https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term = 10[geneid.
4.
Arbor Pharmaceuticals LLC
.
BiDil [package insert]. [cited 2020 June 8]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020727s010lbl.pdf.
Revised 2019 Mar 12
.
5.
Novartis
.
Apresoline [package insert]. [cited 2020 June 8]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf.
Revised 1996 Feb 28
.
6.
FDA
.
Table of Pharmacogenetic Associations. [cited 2020 June 8]. Available from:
https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations.
Revised 2020 Feb 25
.
7.
Taylor
AL
,
Ziesche
S
,
Yancy
C
,
Carson
P
,
D’Agostino
R
 Jr
,
Ferdinand
K
, et al.
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
.
N Engl J Med
.
2004
;
351
(
20
):
2049
57
.
8.
Collins
KS
,
Pratt
VM
,
Stansberry
WM
,
Medeiros
EB
,
Kannegolla
K
,
Swart
M
, et al.
Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy
.
Pharmacogenet Genomics
.
2019
;
29
(
1
):
18
22
.
9.
Spiech
KM
,
Tripathy
PR
,
Woodcock
AM
,
Sheth
NA
,
Collins
KS
,
Kannegolla
K
, et al.
Implementation of a renal precision medicine program: clinician attitudes and acceptance
.
Life
.
2020
;
10
(
4
):
32
.
10.
Gonzalez-Fierro
A
,
Vasquez-Bahena
D
,
Taja-Chayeb
L
,
Vidal
S
,
Trejo-Becerril
C
,
Pérez-Cardenas
E
, et al.
Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype
.
Int J Clin Pharmacol Ther
.
2011
;
49
(
8
):
519
24
.
11.
Han
LW
,
Ryu
RJ
,
Cusumano
M
,
Easterling
TR
,
Phillips
BR
,
Risler
LJ
, et al.
Effect of N-Acetyltransferase 2 genotype on the pharmacokinetics of hydralazine during pregnancy
.
J Clin Pharmacol
.
2019
;
59
(
12
):
1678
89
.
12.
Weber
WW
,
Hein
DW
.
N-acetylation pharmacogenetics
.
Pharmacol Rev
.
1985
;
37
(
1
):
25
79
.
13.
Parkin
DP
,
Vandenplas
S
,
Botha
FJ
,
Vandenplas
ML
,
Seifart
HI
,
van Helden
PD
, et al.
Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis
.
Am J Respir Crit Care Med
.
1997
;
155
(
5
):
1717
22
.
14.
Le Marchand
L
,
Sivaraman
L
,
Franke
AA
,
Custer
LJ
,
Wilkens
LR
,
Lau
AF
, et al.
Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies?
Cancer Epidemiol Biomarkers Prev
.
1996
;
5
(
6
):
449
55
.
15.
Weinshilboum
R
,
Wang
L
.
Pharmacogenomics: bench to bedside
.
Nat Rev Drug Discov
.
2004
;
3
(
9
):
739
48
.
16.
Grant
DM
,
Mörike
K
,
Eichelbaum
M
,
Meyer
UA
.
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver
.
J Clin Invest
.
1990
;
85
(
3
):
968
72
.
17.
Harris
HW
,
Knight
RA
,
Selin
MJ
.
Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications
.
Am Rev Tuberc
.
1958
;
78
(
6
):
944
8
.
18.
Evans
DA
,
Manley
KA
,
McKUSICK
VA
.
Genetic control of isoniazid metabolism in man
.
Br Med J
.
1960
;
2
(
5197
):
485
91
.
19.
Mitchell
RS
,
Bell
JC
.
Clinical implications of isoniazid, PAS and streptomycin blood levels in pulmonary tuberculosis
.
Trans Am Clin Climatol Assoc
.
1957
;
69
(
22
):
98
5
.
20.
Akhter
N
,
Iqbal
T
,
Jamil
A
,
Akram
M
,
Mehmood Tahir
I
,
Munir
N
.
Determination of arylamine N-acetyltransferase 2 acetylation genotype by PCR and phenotyping using dapsone through high-pressure liquid chromatography assay: a gender wise study
.
Dose Response
.
2019
;
17
(
2
):
1559325819855537
.
21.
Aklillu
E
,
Carrillo
JA
,
Makonnen
E
,
Bertilsson
L
,
Djordjevic
N
.
N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in ethiopians
.
Eur J Clin Pharmacol
.
2018
;
74
(
7
):
903
11
.
22.
Al-Ahmad
MM
,
Amir
N
,
Dhanasekaran
S
,
John
A
,
Abdulrazzaq
YM
,
Ali
BR
, et al.
Studies on N-acetyltransferase (NAT2) genotype relationships in emiratis: confirmation of the existence of phenotype variation among slow acetylators
.
Ann Hum Genet
.
2017
;
81
(
5
):
190
6
.
23.
Bell
DA
,
Taylor
JA
,
Butler
MA
,
Stephens
EA
,
Wiest
J
,
Brubaker
LH
, et al.
Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
.
Carcinogenesis
.
1993
;
14
(
8
):
1689
92
.
24.
Birch Kristensen
E
,
Yakimov
V
,
Bjorn-Mortensen
K
,
Soborg
B
,
Koch
A
,
Andersson
M
, et al.
Study of correlation between the NAT2 phenotype and genotype status among greenlandic inuit
.
EXCLI J
.
2018
;
17
:
1043
53
.
25.
Bolt
HM
,
Selinski
S
,
Dannappel
D
,
Blaszkewicz
M
,
Golka
K
.
Re-investigation of the concordance of human NAT2 phenotypes and genotypes
.
Arch Toxicol
.
2005
;
79
(
4
):
196
200
.
26.
Cascorbi
I
,
Drakoulis
N
,
Brockmöller
J
,
Maurer
A
,
Sperling
K
,
Roots
I
.
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity
.
Am J Hum Genet
.
1995
;
57
(
3
):
581
92
.
27.
Cascorbi
I
,
Brockmöller
J
,
Mrozikiewicz
PM
,
Müller
A
,
Roots
I
.
Arylamine N-acetyltransferase activity in man
.
Drug Metab Rev
.
1999
;
31
(
2
):
489
502
.
28.
Deguchi
T
,
Mashimo
M
,
Suzuki
T
.
Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver
.
J Biol Chem
.
1990
;
265
(
22
):
12757
60
.
29.
Díaz-Molina
R
,
Cornejo-Bravo
JM
,
Ramos-Ibarra
MA
,
Estrada-Guzmán
JD
,
Morales-Arango
O
,
Reyes-Báez
R
, et al.
Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis
.
Mol Med Rep
.
2008
;
1
(
6
):
875
9
.
30.
Goldenkova-Pavlova
IV
,
Bruskin
SA
,
Abdeev
RM
,
Markarova
EV
,
Bigvava
SG
,
Radkevich
LA
, et al.
[Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping]
.
Genetika
.
2006
;
42
(
8
):
1143
50
.
31.
Graf
T
,
Broly
F
,
Hoffmann
F
,
Probst
M
,
Meyer
UA
,
Howald
H
.
Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers
.
Eur J Clin Pharmacol
.
1992
;
43
(
4
):
399
403
.
32.
Gross
M
,
Kruisselbrink
T
,
Anderson
K
,
Lang
N
,
McGovern
P
,
Delongchamp
R
, et al.
Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population
.
Cancer Epidemiol Biomarkers Prev
.
1999
;
8
(
8
):
683
92
.
33.
Hein
DW
,
Doll
MA
.
Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes
.
Pharmacogenomics
.
2012
;
13
(
1
):
31
41
.
34.
Hickman
D
,
Sim
E
.
N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans
.
Biochem Pharmacol
.
1991
;
42
(
5
):
1007
14
.
35.
Kaufmann
GR
,
Wenk
M
,
Taeschner
W
,
Peterli
B
,
Gyr
K
,
Meyer
UA
, et al.
N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus
.
Clin Pharmacol Ther
.
1996
;
60
(
1
):
62
7
.
36.
Kuhn
UD
,
Anschütz
M
,
Schmücker
K
,
Schug
BS
,
Hippius
M
,
Blume
HH
.
Phenotyping with sulfasalazine: time dependence and relation to NAT2 pharmacogenetics
.
Int J Clin Pharmacol Ther
.
2010
;
48
(
1
):
1
10
.
37.
O’Neil
WM
,
Gilfix
BM
,
DiGirolamo
A
,
Tsoukas
CM
,
Wainer
IW
.
N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow?
Clin Pharmacol Ther
.
1997
;
62
(
3
):
261
71
.
38.
Rana
SV
,
Ola
RP
,
Sharma
SK
,
Arora
SK
,
Sinha
SK
,
Pandhi
P
, et al.
Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients
.
Hepatol Int
.
2012
;
6
(
1
):
397
402
.
39.
Rihs
HP
,
John
A
,
Scherenberg
M
,
Seidel
A
,
Brüning
T
.
Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay
.
Clin Chim Acta
.
2007
;
376
(
1–2
):
240
3
.
40.
Ruiz
JD
,
Martínez
C
,
Anderson
K
,
Gross
M
,
Lang
NP
,
García-Martín
E
, et al.
The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype
.
PLoS One
.
2012
;
7
(
9
):
e44629
.
41.
Rychlik-Sych
M
,
Skretkowicz
J
,
Gawrońska-Szklarz
B
,
Górnik
W
,
Sysa-Jedrzejowska
A
,
Skretkowicz-Szarmach
K
.
Acetylation genotype and phenotype in patients with systemic lupus erythematosus
.
Pharmacol Rep
.
2006
;
58
(
1
):
22
9
.
42.
Skretkowicz
K
,
Skretkowicz
J
,
Gawrońska-Szklarz
B
,
Górnik
W
,
Rychlik-Sych
M
,
Sysa-Jedrzejowska
A
.
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis
.
Eur J Clin Pharmacol
.
2005
;
60
(
11
):
773
8
.
43.
Smith
CA
,
Wadelius
M
,
Gough
AC
,
Harrison
DJ
,
Wolf
CR
,
Rane
A
.
A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid
.
J Med Genet
.
1997
;
34
(
9
):
758
60
.
44.
Straka
RJ
,
Burkhardt
RT
,
Lang
NP
,
Hadsall
KZ
,
Tsai
MY
.
Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects
.
J Clin Pharmacol
.
2006
;
46
(
7
):
802
11
.
45.
Wolkenstein
P
,
Loriot
MA
,
Aractingi
S
,
Cabelguenne
A
,
Beaune
P
,
Chosidow
O
.
Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS
.
Pharmacogenetics
.
2000
;
10
(
9
):
821
8
.
46.
Woolhouse
NM
,
Qureshi
MM
,
Bastaki
SM
,
Patel
M
,
Abdulrazzaq
Y
,
Bayoumi
RA
.
Polymorphic N-acetyltransferase (NAT2) genotyping of emiratis
.
Pharmacogenetics
.
1997
;
7
(
1
):
73
82
.
47.
Zhao
B
,
Seow
A
,
Lee
EJ
,
Lee
HP
.
Correlation between acetylation phenotype and genotype in Chinese women
.
Eur J Clin Pharmacol
.
2000
;
56
(
9–10
):
689
92
.
48.
Selinski
S
,
Blaszkewicz
M
,
Getzmann
S
,
Golka
K
.
N-Acetyltransferase 2: ultra-slow acetylators enter the stage
.
Arch Toxicol
.
2015
;
89
(
12
):
2445
7
.
49.
Timbrell
JA
,
Harland
SJ
,
Facchini
V
.
Effect of dose on acetylator phenotype distribution of hydralazine
.
Clin Pharmacol Ther
.
1981
;
29
(
3
):
337
43
.
50.
Allen
CE
,
Doll
MA
,
Hein
DW
.
N-Acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes
.
Drug Metab Dispos
.
2017
;
45
(
12
):
1276
81
.
51.
Arce
C
,
Pérez-Plasencia
C
,
González-Fierro
A
,
de la Cruz-Hernández
E
,
Revilla-Vázquez
A
,
Chávez-Blanco
A
, et al.
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer
.
PLoS One
.
2006
;
1
:
e98
.
52.
Candelaria
M
,
Gallardo-Rincón
D
,
Arce
C
,
Cetina
L
,
Aguilar-Ponce
JL
,
Arrieta
O
, et al.
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
.
Ann Oncol
.
2007
;
18
(
9
):
1529
38
.
53.
Facchini
V
,
Timbrell
JA
.
Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man
.
Br J Clin Pharmacol
.
1981
;
11
(
4
):
345
51
.
54.
Ludden
TM
,
McNay
JL
 Jr
,
Shepherd
AM
,
Lin
MS
.
Variability of plasma hydralazine concentrations in male hypertensive patients
.
Arthritis Rheum
.
1981
;
24
(
8
):
987
93
.
55.
Rashid
JR
,
Kofi-Tsepko
T
,
Juma
FD
.
Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital
.
East Afr Med J
.
1992
;
69
(
7
):
406
8
.
56.
Shepherd
AM
,
Ludden
TM
,
McNay
JL
,
Lin
MS
.
Hydralazine kinetics after single and repeated oral doses
.
Clin Pharmacol Ther
.
1980
;
28
(
6
):
804
11
.
57.
Timbrell
JA
,
Harland
SJ
.
Identification and quantitation of hydrazine in the urine of patients treated with hydralazine
.
Clin Pharmacol Ther
.
1979
;
26
(
1
):
81
8
.
58.
Timbrell
JA
,
Harland
SJ
,
Facchini
V
.
Polymorphic acetylation of hydralazine
.
Clin Pharmacol Ther
.
1980
;
28
(
3
):
350
5
.
59.
Zacest
R
,
Koch-Weser
J
.
Relation of hydralazine plasma concentration to dosage and hypotensive action
.
Clin Pharmacol Ther
.
1972
;
13
(
3
):
420
5
.
60.
Garcés-Eisele
SJ
,
Cedillo-Carvallo
B
,
Reyes-Núñez
V
,
Estrada-Marín
L
,
Vázquez-Pérez
R
,
Juárez-Calderón
M
, et al.
Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure
.
J Clin Pharm Ther
.
2014
;
39
(
4
):
368
75
.
61.
Graves
DA
,
Muir
KT
,
Richards
W
,
Steiger
BW
,
Chang
I
,
Patel
B
.
Hydralazine dose-response curve analysis
.
J Pharmacokinet Biopharm
.
1990
;
18
(
4
):
279
91
.
62.
Jounela
AJ
,
Pasanen
M
,
Mattila
MJ
.
Acetylator phenotype and the antihypertensive response to hydralazine
.
Acta Med Scand
.
1975
;
197
(
4
):
303
6
.
63.
Kalowski
S
,
Hua
AS
,
Whitworth
JA
,
Kincaid-Smith
P
.
Hydrallazine with beta-blocker and diuretic in the treatment of hypertension. A double-blind crossover study
.
Med J Aust
.
1979
;
2
(
8
):
439
40
.
64.
Rowell
NP
,
Clark
K
.
The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status
.
Radiother Oncol
.
1990
;
18
(
4
):
293
8
.
65.
Shepherd
A
,
Lin
MS
,
McNay
J
,
Ludden
T
,
Musgrave
G
.
Determinants of response to intravenous hydralazine in hypertension
.
Clin Pharmacol Ther
.
1981
;
30
(
6
):
773
81
.
66.
Shepherd
AM
,
McNay
JL
,
Ludden
TM
,
Lin
MS
,
Musgrave
GE
.
Plasma concentration and acetylator phenotype determine response to oral hydralazine
.
Hypertension
.
1981
;
3
(
5
):
580
5
.
67.
Hunyor
SN
.
Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype
.
Aust N Z J Med
.
1975
;
5
(
6
):
530
6
.
68.
Spinasse
LB
,
Santos
AR
,
Suffys
PN
,
Muxfeldt
ES
,
Salles
GF
.
Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension
.
Pharmacogenomics
.
2014
;
15
(
2
):
169
78
.
69.
Sherry
ST
,
Ward
M
,
Sirotkin
K
.
dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation
.
Genome Res
.
1999
;
9
(
8
):
677
9
.
70.
Batchelor
JR
,
Welsh
KI
,
Tinoco
RM
,
Dollery
CT
,
Hughes
GR
,
Bernstein
R
, et al.
Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility
.
Lancet
.
1980
;
1
(
8178
):
1107
9
.
71.
Cameron
HA
,
Ramsay
LE
.
The lupus syndrome induced by hydralazine: a common complication with low dose treatment
.
Br Med J
.
1984
;
289
(
6442
):
410
2
.
72.
Ihle
BU
,
Whitworth
JA
,
Dowling
JP
,
Kincaid-Smith
P
.
Hydralazine and lupus nephritis
.
Clin Nephrol
.
1984
;
22
(
5
):
230
8
.
73.
Whelton
PK
,
Carey
RM
,
Aronow
WS
,
Casey
DE
 Jr
,
Collins
KJ
,
Dennison Himmelfarb
C
, et al.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
.
J Am Coll Cardiol
.
2018
;
71
(
6
):
1269
324
.
74.
Morrow
JD
,
Schroeder
HA
,
Perry
HM
 Jr
.
Studies on the control of hypertension by hyphex. II. Toxic reactions and side effects
.
Circulation
.
1953
;
8
(
6
):
829
39
.
75.
Zschieschang
P
,
Hiepe
F
,
Gromnica-Ihle
E
,
Roots
I
,
Cascorbi
I
.
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus
.
Pharmacogenetics
.
2002
;
12
(
7
):
559
63
.
76.
Baer
AN
,
Woosley
RL
,
Pincus
T
.
Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus
.
Arthritis Rheum
.
1986
;
29
(
4
):
508
14
.
77.
Shiokawa
S
,
Yasuda
M
,
Nobunaga
M
.
Genotypes of polymorphic arylamine N-acetyltransferase in systemic lupus erythematosus
.
Arthritis Rheum
.
1992
;
35
(
11
):
1397
9
.
78.
Vedove
CD
,
Del Giglio
M
,
Schena
D
,
Girolomoni
G
.
Drug-induced lupus erythematosus
.
Arch Dermatol Res
.
2009
;
301
(
1
):
99
105
.
79.
Lexicomp online. Lexi-drugs
.
Hudson, OH
:
Wolters Kluwer Clinical Drug Information Inc
;
2020
.
Updated 2020 Jun 6
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.